These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 30459509)
1. Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA. Heo YA Drugs Ther Perspect; 2018; 34(11):507-512. PubMed ID: 30459509 [TBL] [Abstract][Full Text] [Related]
2. Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban. Abuan I; Wong KH; Bolinske B; Hale KS J Pharm Technol; 2019 Jun; 35(3):119-125. PubMed ID: 34860981 [No Abstract] [Full Text] [Related]
6. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ; Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876 [TBL] [Abstract][Full Text] [Related]
7. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Carpenter E; Singh D; Dietrich E; Gums J Ther Adv Drug Saf; 2019; 10():2042098619888133. PubMed ID: 31807265 [TBL] [Abstract][Full Text] [Related]
8. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140 [TBL] [Abstract][Full Text] [Related]
9. Andexanet alfa for the reversal of factor Xa inhibitors. Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977 [TBL] [Abstract][Full Text] [Related]
10. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy. Sartori M; Cosmi B J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400 [TBL] [Abstract][Full Text] [Related]
11. Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of Hematology. Angelillo-Scherrer A; Casini A; Studt JD; Gerber B; Alberio LA; Fontana P Swiss Med Wkly; 2023 Jul; 153():40113. PubMed ID: 37499160 [TBL] [Abstract][Full Text] [Related]
12. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA). Rogers KC; Finks SW Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385 [TBL] [Abstract][Full Text] [Related]
13. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series. Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614 [TBL] [Abstract][Full Text] [Related]
14. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. Abdulrehman J; Eikelboom JW; Siegal DM Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083 [TBL] [Abstract][Full Text] [Related]